EATG » FDA grants Priority Review to HIV monoclonal antibody ibalizumab

FDA grants Priority Review to HIV monoclonal antibody ibalizumab

FDA grants Priority Review to HIV monoclonal antibody and long-acting investigational antiretroviral ibalizumab

— Biologics License Application accepted for review with a target action date of January 3, 2018

— Ibalizumab expanded access program currently enrolling new patients

Read the full press release here.

Share on FacebookTweet about this on TwitterShare on Google+Pin on PinterestShare on LinkedIn
Source:
Theratechnologies Inc.
News categories: EMA/FDA